DKK754.00
1.15% today
Copenhagen, Nov 26, 12:46 pm CET
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Novo Nordisk Stock price

DKK745.40
-38.90 4.96% 1M
-174.30 18.95% 6M
+47.30 6.78% YTD
+35.40 4.99% 1Y
+385.40 107.06% 3Y
+555.23 291.95% 5Y
+612.15 459.40% 10Y
Copenhagen, Closing price Mon, Nov 25 2024
-5.50 0.73%
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Key metrics

Market capitalization DKK3.29t
Enterprise Value DKK3.27t
P/E (TTM) P/E ratio 35.08
EV/FCF (TTM) EV/FCF 42.08
EV/Sales (TTM) EV/Sales 12.09
P/S ratio (TTM) P/S ratio 12.16
P/B ratio (TTM) P/B ratio 27.30
Dividend yield 1.26%
Last dividend (FY23) DKK9.40
Revenue growth (TTM) Revenue growth 26.15%
Revenue (TTM) Revenue DKK270.58b
EBIT (operating result TTM) EBIT DKK118.63b
Free Cash Flow (TTM) Free Cash Flow DKK77.75b
Cash position DKK74.88b
EPS (TTM) EPS DKK21.25
P/E forward 33.07
P/S forward 11.48
EV/Sales forward 11.42
Show more

Is Novo Nordisk a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Novo Nordisk Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Novo Nordisk forecast:

20x Buy
63%
8x Hold
25%
4x Sell
13%

Analyst Opinions

32 Analysts have issued a Novo Nordisk forecast:

Buy
63%
Hold
25%
Sell
13%

Financial data from Novo Nordisk

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
270,583 270,583
26% 26%
100%
- Direct Costs 41,512 41,512
22% 22%
15%
229,071 229,071
27% 27%
85%
- Selling and Administrative Expenses 48,821 48,821
2% 2%
18%
- Research and Development Expense 44,720 44,720
49% 49%
17%
135,530 135,530
34% 34%
50%
- Depreciation and Amortization 16,901 16,901
100% 100%
6%
EBIT (Operating Income) EBIT 118,629 118,629
28% 28%
44%
Net Profit 94,721 94,721
26% 26%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Novo Nordisk directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Head office Denmark
CEO Lars Jørgensen
Employees 63,370
Founded 1931
Website www.novonordisk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today